This software bot accelerates and streamlines the scheduling of hundreds of thousands of patient appointments to receive the two-shot vaccine for COVID-19.
Clalit Health Services, the largest healthcare maintenance organization in Israel, has already used the Kryon V-Bot to schedule more than 100,000 vaccine appointments per day.
Israel leads the world in COVID vaccinations and having already vaccinated 30% of its eight m citizens.
The logistical problems facing healthcare organizations attempting a controlled COVID-19 vaccine roll-out are astounding.
Many hospitals, healthcare providers and HMOs receive vaccines with little notice, placing enormous stress on support staff to schedule last minute appointments and use every available dose.
By automating scheduling based on eligibility criteria, the burden is lifted allowing them to focus on areas that require a human touch, like patient care and service.
Kryon is offering the V-Bot to all healthcare providers to expedite the required double-appointment setting. The purchase of Kryon V-Bot includes an unlimited amount of software bots to assist in the mass scheduling.
Further, Kryon will also customize the automation workflow of an organization's patient scheduling process based on an individual organization's structure and needs.
Kryon is in enterprise automation, offering the only platform on the market which encompasses both Process Discovery technology and Robotic Process Automation (RPA).
The Kryon Full-Cycle Automation solution maximizes ROI by 352% according to Forrester Research and cuts RPA implementation time by up to 80%.
Powered by proprietary AI technology, Kryon Process Discovery automatically generates a comprehensive picture of business processes, evaluates them, and recommends which ones to automate.
Kryon offers desktop-based attended RPA, virtual-machine-based unattended RPA, or a hybrid combination of both. The company's award-winning suite is used by enterprises worldwide, including AIG, Allianz, Deutsche Telekom, EY, Ferring Pharmaceuticals, HP, Microsoft, Santander Bank, Singtel, Verizon, and Wyndham Hotel Group.
GSK reports positive Phase III data for low-carbon version of Ventolin inhaler
Terns Pharmaceuticals reports topline 12-week data from Phase 2 trial of TERN-601 in obesity
The Los Angeles Trust for Children's Health Appoints Dr Sarah Rodman as New Executive Director
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Genentech's Gazyva (obinutuzumab) receives US FDA approval to treat adults with lupus nephritis
ACG to invest USD200m in US hard-shell capsule manufacturing
Charles River and X-Chem form strategic collaboration to accelerate hit identification
Merck reports long-term survival benefits of Keytruda in non-small cell lung cancer
Avacta reports promising Phase 1a data for faridoxorubicin at ESMO 2025